1004-23-5

Basic information

• Product Name: 4-Aminomethyl-phenol hydrochloride
• CAS NO: 1004-23-5
• Molecular Formula: C₇H₉NO*ClH
• Molecular Weight: 159.6134
• Mol File: 1004-23-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Aminomethyl-phenol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Aminomethyl-phenol hydrochloride(1004-23-5)
• EPA Substance Registry System: 4-Aminomethyl-phenol hydrochloride(1004-23-5)

Safety Data

• Hazardous Substances Data: 1004-23-5(Hazardous Substances Data)

Usage

Uses

Used in Hair Dye Industry:
4-Aminomethyl-phenol hydrochloride is used as a color precursor in oxidative hair dye formulations for its ability to react with hydrogen peroxide, producing the desired hair color. It also acts as a stabilizer and antioxidant, enhancing the performance and longevity of the hair dye.
Used in Pharmaceutical Industry:
4-Aminomethyl-phenol hydrochloride may have applications in the synthesis of pharmaceuticals and other organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 4-Aminomethyl-phenol hydrochloride can be utilized as a building block or intermediate in the synthesis of various organic compounds, expanding its potential applications in different industries.
Safety Precautions:
It is crucial to handle 4-Aminomethyl-phenol hydrochloride with care, as it can be harmful if swallowed, inhaled, or in contact with skin. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, should be taken when working with this chemical to minimize potential risks.

Upstream product

• 699-06-9 4-hydroxybenzaldehyde oxime 
• 123-08-0 4-hydroxy-benzaldehyde 
• 767-00-0 4-cyanophenol 

Downstream Products

• 46921-53-3 4-benzothiazol-2-yloxy-benzylamine 
• 365571-97-7 4-bromo-5-[N-[(4-hydroxyphenyl)methyl]-2-aminoethyl]-2-methoxyphenol 
• 188922-39-6 N,N'-bis(benzyloxycarbonyl)-N''-4-hydroxybenzylguanidine 
• 110505-75-4 T1-11 
• 365571-98-8 N-[2-(2-bromo-5-hydroxy-4-methoxyphenyl)-ethyl]-N-[(4-hydroxyphenyl)methyl]-formamide 
• 875012-89-8 (1aS,5aR)-1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 4-hydroxy-benzylamide 
• 55458-49-6 1-acetoxy-4-(acetylamino-methyl)-benzene 
• 149505-94-2 tert-butyl (4-hydroxybenzyl)carbamate 
• 849996-79-8 N-(4-hydroxyphenyl)methyl-2-aminonicotinic acid amide 
• 1287220-37-4 4-((4-((4-hydroxybenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzoic acid 
• 1287220-38-5 tert-butyl 4-(2-hydroxy-3-(4-(4-(4-hydroxybenzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamido)propyl)piperazine-1-carboxylate 
• 1287220-86-3 methyl 4-(4-(4-(but-3-enyloxy)benzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-87-4 4-(4-(4-(but-3-enyloxy)benzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid 
• 1287220-88-5 N-(allylsulfonyl)-4-(4-(4-(but-3-enyloxy)benzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamide 

Relevant articles and documents

Neuroprotective principles from Gastrodia elata

Serum deprivation-induced neuronal-like PC12 cell apoptosis was used as an ischemic/hypoxic model to screen neuroprotective compounds from the rhizomes of Gastrodia elata, a traditional Chinese medicine. Two active compounds, bis(4-hydroxybenzyl)sulfide (

Selective Hydrogenation of Nitriles to Primary Amines Catalyzed by a Polysilane/SiO2-Supported Palladium Catalyst under Continuous-Flow Conditions

Hydrogenation of nitriles to primary amines with heterogeneous catalysts under liquid-phase continuous-flow conditions is described. Newly developed polysilane/SiO2-supported Pd was found to be an effective catalyst and various nitriles were converted into primary amine salts in almost quantitative yields under mild reaction conditions. Interestingly, a complex mixture was obtained under batch conditions. Lifetime experiments showed that this catalyst remained active for more than 300 h (TON≥10 000) without loss of selectivity and no metal leaching from the catalyst occurred. By using this continuous-flow hydrogenation, synthesis of venlafaxine, an antidepressant drug, has been accomplished.

Fabrication of ω-Transaminase@Metal-Organic Framework Biocomposites for Efficiently Synthesizing Benzylamines and Pyridylmethylamines

In this study, ten ω-transaminases (ω-TAs) have been investigated to efficiently catalyze the synthesis of twenty-four functionalized benzylamines and pyridylmethylamines. We optimized the reactions, screened suitable amino donors and compared ω-transaminases activities for all aromatic aldehyde substrates. Under the optimized conditions, eighteen aromatic amines have been obtained with 60.4%–96.6% conversions and isolated only via simple extraction and recrystallization with 18.5%–81% yields on a preparative scale. Furthermore, we first immobilized the Bm-STA onto the MOFs via the physical adsorption to overcome the limitation of free enzyme and improve their industrial applications. The obtained Bm-STA/UiO-66-NH2 composites exhibited not only high enzymes loading (80.4 mg g?1) and enzyme activity recovery (95.8%), but also the better reusability, storage stability, pH stability and the tolerance to acetone and DMF.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

1,2,3-Trimethoxypropane, a glycerol-based solvent with low toxicity: New utilization for the reduction of nitrile, nitro, ester, and acid functional groups with TMDS and a metal catalyst

1,2,3-Trimethoxypropane (1,2,3-TMP) was prepared from glycerol in one step in good yield and selectivity by phase transfer catalysis. According to OECD guidelines, a toxicity study was realized for this compound. It revealed that 1,2,3-TMP has a low acute toxicity, no skin sensitization, no mutagenicity and no ecotoxicity in an aquatic environment. This compound was also used as a solvent for the reduction of organic functions using either aluminium hydride or 1,1,3,3-tetramethyldisiloxane (TMDS) as a benign hydride source. In particular, a new process for the reduction of nitriles to amines in 2-MeTHF and in 1,2,3-TMP was developed, using TMDS in combination with copper triflate (Cu(OTf)2).

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Design and Synthesis of Novel Dual-Action Compounds Targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection

A novel compound, N6-(4-hydroxybenzyl)adenosine, isolated from Gastrodia elata and which has been shown to be a potential therapeutic agent for preventing and treating neurodegenerative disease, was found to target both the adenosine A2A/

AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME

A amid compound of the formula (1): wherein, in the formula, R51 represents a halogen atom, a C1-C6 alkyl group and the like; R52 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group and the like; R53 represents a halogen atom and the like; R56 represents a halogen atom and the like; R57 represents a hydrogen atom and the like; R58 and R59 independently represent a hydrogen atom, a C1-C3 alkyl group and the like; R60 represents a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C3-C4 alkenyl group, or a C3-C6 alkynyl group; R61 represents a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C3-C4 alkenyl group or a C3-C6 alkynyl group or a C2-C4 cyanoalkyl group; R62, R63 and R64 represent a hydrogen atom, a halogen atom and the like; X represents a oxygen atom or a sulfur atom; has an excellent activity against plant diseases.